NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Pluri Inc. PLUR
16 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.3M
▲ 309.8% vs FY2023
EPS · FY24
$-3.56
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-1690.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3M
Revenue, FY2024 · full 16-year series below
Revenue
Net income
The company lost 1690 cents on every revenue dollar this year.
Per share
USD -3.56
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-1659.9%
Net margin-1690.3%
Return on assets-57.7%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+125.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+78.7%
+125.3%
+13.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years+108.7%
Change, 10 years—
The share count grew 109% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 38.7M
total assets, end of FY2024
Total assetsUSD 38.7M
EquityUSD -6.8M
CashUSD 5.9M
Current ratio0.68×
Equity funds -18% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.56
−3.99
−6.24
−1.28
−1.77
−1.60
−2.90
−2.50
−3.20
−0.29
−0.35
−0.42
−0.38
−0.34
−0.35
−0.44
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
−310.6
−130.5
−94.6
−88.1
−74.8
−140.3
−88.9
−81.3
−48.3
−41.0
−45.0
−44.4
−36.5
−45.8
−187.2
Shares out B
0.01
0.01
0.01
0.03
0.03
0.03
0.02
0.01
0.10
0.08
0.08
0.07
0.06
0.05
0.04
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed